.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ESTIMABL2 randomized trial evaluated whether patients with low-risk differentiated thyroid cancer could safely avoid routine postoperative radioactive iodine after thyroid surgery. The study found that a no-radioiodine strategy was non-inferior for the primary disease-control endpoint in appropriately selected low-risk patients. This is an important example of treatment de-escalation in endocrine oncology: once a cancer has been completely or appropriately resected and classified as low risk, additional ablation is not automatically required for every patient. For endocrine surgeons, the practical implication is that postoperative management should be based on individualized recurrence risk rather than a one-size-fits-all protocol. Decisions must integrate pathology, surgical completeness, staging, thyroglobulin monitoring and the planned follow-up pathway. Avoiding unnecessary radioactive iodine can reduce treatment burden and prevent potential adverse effects while preserving excellent disease control in selected patients. The trial therefore strengthens a more conservative, risk-adapted approach to differentiated thyroid cancer care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ESTIMABL2 randomized trial evaluated whether patients with low-risk differentiated thyroid cancer could safely avoid routine postoperative radioactive iodine after thyroid surgery. The study found that a no-radioiodine strategy was non-inferior for the primary disease-control endpoint in appropriately selected low-risk patients. This is an important example of treatment de-escalation in endocrine oncology: once a cancer has been completely or appropriately resected and classified as low risk, additional ablation is not automatically required for every patient. For endocrine surgeons, the practical implication is that postoperative management should be based on individualized recurrence risk rather than a one-size-fits-all protocol. Decisions must integrate pathology, surgical completeness, staging, thyroglobulin monitoring and the planned follow-up pathway. Avoiding unnecessary radioactive iodine can reduce treatment burden and prevent potential adverse effects while preserving excellent disease control in selected patients. The trial therefore strengthens a more conservative, risk-adapted approach to differentiated thyroid cancer care.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
3 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
